

**Amendments to the Claims:**

1. (Cancelled)
2. (Currently amended) A molecule ~~comprising~~ selected from the group consisting of complement control protein modules 1-4, 1-5 [[or]], and 1-6 of complement factor H.
- 3-4. (Cancelled)
5. (Withdrawn) A molecule according to claim 2, comprising complement control protein modules 1-6, and having the sequence of SEQ ID NO: 11.
6. (Withdrawn) A molecule according to claim 1, the complement factor H being rat complement factor H.
7. (Withdrawn) A complement system inhibiting molecule comprising complement control protein modules 1-7 of rat complement factor H and having the sequence of SEQ ID NO: 14.
8. (Withdrawn) A molecule according to any one of claims 1-7, for use in inhibiting complement activation.
- 9-10. (Cancelled)
11. (Withdrawn) A method of manufacture of a medicament for inhibiting complement activation, comprising the use of a molecule according to any one of claims 1-9.
12. (Withdrawn) A method of inhibiting complement activation comprising the use of a molecule according to any one of claims 1-9.

13. (Withdrawn) A nucleotide sequence having the formula of SEQ ID NO: 1 and encoding rat FH 4.3 kb mRNA.

14. (Withdrawn) A nucleotide sequence having the formula of SEQ ID NO:2 and encoding rat FH 1.0 mRNA.

15. (Withdrawn) A DNA molecule comprising a sequence encoding a module according to any one of claims 1-9.

16. (Withdrawn) A DNA molecule comprising a sequence encoding a molecule according to any one of claims 1-10.

17. (Currently amended) A molecule ~~comprising~~ consisting of complement control protein modules, wherein said complement control protein modules are modules 1-4 of complement factor H.

18. (Previously presented) The molecule of claim 17 wherein the complement factor H is human complement factor H.

19. (Previously presented) The molecule according to claim 18, wherein the complement control protein modules 1-4 have the sequence of SEQ ID NO: 9.

20-21. (Cancelled)

22. (Currently amended) A molecule ~~with complement inhibitory activity comprising~~ consisting of complement control protein modules selected from the group consisting of ~~only~~

complement control protein modules 1-4, 1-5, and 1-6 of complement factor H, wherein the molecule is useful for inhibition of complement activation.

23. (Previously presented) The molecule according to claim 22, the complement factor H being human complement factor H.

24–25. (Cancelled)

26. (Currently amended) The molecule of claim 17 ~~comprising~~ consisting of complement control protein modules 1-4 of FHp43.

27–29. (Cancelled)

30. (Previously presented) The molecule according to claim 17, coupled to artificial membranes by activating the membrane, coupling of spacers, and coupling of the peptide.

31. (Currently amended) The molecule of claim 17 wherein said complement control protein modules ~~have a sequence of~~ consisting of 207 amino acids.

32. (Previously presented) The molecule according to claim 22, the complement factor being an animal complement factor H.

33–35. (Cancelled)

36. (Currently amended) A truncated recombinant factor H ~~comprising at least~~ consisting of complement control protein modules 1-4 selected from the group consisting of complement control protein modules 1-6, 1-5, and 1-4 of complement factor H.